As per the report published by Kings Research, the global Real Time Polymerase Chain Reaction Systems Market was valued at USD 4.93 billion in 2022 and is projected to reach USD 7.01 billion by 2030, growing at a CAGR of 4.57% from 2023 to 2030.

The increasing demand for current qPCR systems has expanded owing to the prevalence of chronic diseases. In response to this growing health problem, there is a mounting demand for advanced diagnostic tools and technologies. Although qPCR technology has traditionally been used in research, clinical laboratories are increasingly using it for diagnostic purposes. This change is due to the continuous development of new qPCR assays that can detect specific disease biomarkers with high sensitivity and specificity. In recent years, qPCR assays have been developed for various applications, including the detection of infectious diseases, genetic disorders, and cancer. Real-time polymerase chain reaction (PCR) technology has become a prominent tool in many molecular biology applications, including pathogen detection, gene expression analysis, and drug development, which propels the market expansion.

Key Insights

• Based on type, the specific detection segment is growing at a CAGR of 4.97% over the forecast period
• Based on product, the reagents & consumables segment is expected to dominate over the forecast period
• Based on application, the gene expression analysis segment is expected to dominate the market over the forecast period with a CAGR of 3.93%
• On the basis of region, North America accounted for the highest market value of USD 2.12 billion in 2022

Thermo Fisher Scientific Receives FDA Approval to Expand its Product Portfolio

March 2021: Thermo Fisher Scientific completed FDA listing for the Applied Biosystems QuantStudio 5 Dx Real-Time PCR System. The product enables clinical laboratories and test developers to meet testing requirements and improve their molecular diagnostic workflows.

Rising Frequency of Infectious Diseases Drives the Need for Real-Time Polymerase Chain Reaction (PCR) Systems

Infectious diseases are a major public health problem, affecting millions of people worldwide each year. Real-time polymerase chain reaction (PCR) systems are a powerful and highly sensitive diagnostic tool that can rapidly detect and identify the causes of infectious diseases. As the incidence of infectious diseases continues to increase, there is increasing interest in the use of real-time PCR systems to improve the diagnosis, surveillance, and control of infectious diseases. In addition to the advantages of real-time PCR in the diagnosis and monitoring of infectious illnesses, this technology is also used in the study of molecular epidemiology of infectious diseases. Real-time PCR can be used to sequence the genetic material of pathogens, helping to identify strains, track disease outbreaks, and track the evolution of infectious agents over time. The continued research and development in this area has led to improvements in the sensitivity, specificity, and speed of real-time PCR-based diagnostic tests, enabling more accurate and efficient diagnosis and treatment of infectious diseases.

Emerging Innovations in real-time PCR technology Provides Lucrative Opportunities in the Market

Recent innovations in real-time PCR technology have focused on making the process faster, more sensitive, and less expensive. The use of microfluidic devices has enabled the development of portable, point-of-care, real-time PCR systems that can provide results in minutes. The development of new probe chemistries, such as hybridization probes and locked nucleic acid probes, has improved the sensitivity and specificity of real-time PCR assays. Digital PCR is a variant of PCR that involves dividing a sample into thousands or millions of individual droplets or compartments, each of which undergoes PCR independently. This results in very accurate quantification of the precursor even at very low levels. Moreover, real-time PCR technology is a rapidly developing field with many emerging developments that are more versatile, and have the potential to revolutionize many areas of molecular biology research.

North America is Expected to Dominate Over the Forecast Period with a Value of USD 3.03 Billion by 2030

The regional market growth is proliferated by expanding applications in cancer research, pathogen detection, and environmental monitoring.  In addition to the growing demand for dPCR technology in scientific applications, there is also a growing interest in the use of dPCR in clinical diagnostics. The increasing incidence of chronic diseases such as cancer and diabetes increases the demand for advanced diagnostic technologies that can accurately and reliably detect disease biomarkers. dPCR is well positioned to play a key role in this field because it provides high sensitivity and specificity for the detection of specific nucleic acid sequences. Real-time PCR can be used to sequence the genetic material of pathogens, helping to identify strains, track disease outbreaks, and trace the evolution of infectious agents over time, which is fostering market growth.

Europe is the Second Dominating Region with a Market Value of USD 1.47 Billion in 2030

The regional market share is increasing on account of the availability of advanced diagnostic technologies such as real-time PCR is likely to continue to grow. In addition, continued research and development in this area will likely lead to improvements in the sensitivity, specificity, and speed of real-time PCR-based diagnostic tests, allowing more accurate and efficient diagnosis and treatment of infectious diseases. The availability of next-generation diagnostic technology digital PCR for precise nucleic acid measurement, which has higher sensitivity and accuracy than other PCR-based techniques, is expected to drive the market forward. Moreover, the increasing introduction of innovative Droplet Digital PCR tests is anticipated to increase the application expansion over the forecast period.

Significant Number of Players are Launching Cutting-Edge Products to Exceed their Reach

The global real time polymerase chain reaction systems market growth is accelerated by the presence of market players such as Abbott, Agilent Technologies Inc, Becton, Dickinson and Company, BIOMÉRIEUX, Bio-Rad Laboratories, Inc., Danaher Corporation, F. Hoffmann-La Roche Ltd, Lumex Instruments, Merck KGaA, Takara Bio Inc., Thermo Fisher Scientific Inc., and others. These players are focusing on several key business strategies, such as partnerships, mergers and acquisitions, product innovations, and joint ventures, to expand their product portfolio and increase their respective market shares across different regions.